NM_001114753.3:c.690-1G>A
Variant summary
Our verdict is Pathogenic. The variant received 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_001114753.3(ENG):c.690-1G>A variant causes a splice acceptor, intron change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 2/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_001114753.3 splice_acceptor, intron
Scores
Clinical Significance
Conservation
Publications
- telangiectasia, hereditary hemorrhagic, type 1Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), G2P, Genomics England PanelApp, ClinGen
- hereditary hemorrhagic telangiectasiaInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- juvenile polyposis syndromeInheritance: AD Classification: LIMITED Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 18 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| ENG | NM_001114753.3 | c.690-1G>A | splice_acceptor_variant, intron_variant | Intron 5 of 14 | ENST00000373203.9 | NP_001108225.1 | ||
| ENG | NM_000118.4 | c.690-1G>A | splice_acceptor_variant, intron_variant | Intron 5 of 13 | NP_000109.1 | |||
| ENG | NM_001278138.2 | c.144-1G>A | splice_acceptor_variant, intron_variant | Intron 5 of 14 | NP_001265067.1 | |||
| ENG | NM_001406715.1 | c.690-1G>A | splice_acceptor_variant, intron_variant | Intron 5 of 7 | NP_001393644.1 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 26
GnomAD4 exome Cov.: 33
GnomAD4 genome Cov.: 26
ClinVar
Submissions by phenotype
Cardiovascular phenotype Pathogenic:1
The c.690-1G>A intronic pathogenic mutation results from a G to A substitution one nucleotide upstream from coding exon 6 of the ENG gene. This mutation was previously detected in a patient with epistaxis and family history of hereditary hemorrhagic telangiectasia (HHT) (Argyriou L, Int. J. Mol. Med. 2006 Apr; 17(4):655-9). In addition to the clinical data presented in the literature, alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation. -
Hereditary hemorrhagic telangiectasia Pathogenic:1
For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 458351). Disruption of this splice site has been observed in individuals with hereditary hemorrhagic telangiectasia (PMID: 10625079, 16525724, 22991266). This variant is not present in population databases (gnomAD no frequency). This sequence change affects an acceptor splice site in intron 5 of the ENG gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in ENG are known to be pathogenic (PMID: 15879500). -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at